KWA Public Relations, LLC – October 25, 2024, 14:00 GMT
Transcatheter aortic valve is developed with next-generation polymer to improve both durability and biocompatibility
ATLANTA, GA, UNITED STATES, October 25, 2024 /EINPresswire.com/ — Todd Tomba, president and CEO, YoungHeartValve, Inc., announced today that the company has received $2.8 million in additional National Institutes of Health SBIR grant funding to continue to test its product in development, The Rejuvenate Valve. This most recent grant award brings the technology’s total non-dilutive funding to $6.5 million.
This unique trans-catheter valve technology features novel, molecular level, engineered, polymeric leaflets with natural biomolecules, making it durable and highly hydrophillic with proven resistance to blood clotting and calcification. In addition to freedom from reliance on animal tissue, the technology promises ease of mass production.
“Our technology will provide both next-level durability and unprecedented hemocompatibility, compared to the gold standard heart valves on the market today,” said Tomba. “We’re making incredible progress toward a long-lasting transcatheter valve that is free from animal tissue and does not require life-long anticoagulation therapy.”
YoungHeartValve’s technology features a unique, patented, polymer-based leaflet and a ‘built for purpose’ stent. Rather than tediously sewing the leaflets to the stent, a proprietary system is used to mount the leaflets.
“The Rejuvenate Valve is the only polymeric heart valve that physically incorporates a biomolecule present in human blood vessels and the natural valve leaflet, hyaluronan,” said Co-founder and COO Susan James, PhD. This unique interpenetrating network between the durable engineering plastic and the natural polymer prevents blood clotting and prevents calcification.
“Our valves are engineered for lifetime patient care that is truly designed for the world with the capability of mass production and simply a better device from the standpoint of performance, best-in-class features, and durability. Fixed animal tissue-based valves may be a thing of the past, ” said Co-Founder and CTO Lakshmi Prasad Dasi, PhD.
The company is currently in the preclinical design verification and validation phase of development.
Note: YoungHeartValve will be featured at TCT 2024 on Monday, October 28, 11 a.m., as part of the Innovation in TAVR Systems and New Clinical Updates presentations. The event will be held at the Walter E. Washington Convention Center, Lower Level, Innovation & Exhibit Hall, Innovation Theater.
Investor contact: Todd Tomba, todd.tomba@youngheartvalve.com, 614.565.8493
